NewsRoom Articles - Page 11 of 37

ThursdayAug 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Intent for Human Clinical Study for Diabetes and Weight Loss Following Positive DehydraTECH(TM)-CBD Results in Animals

Lexaria’s patented DehydraTECH(TM)-CBD achieved promising results for diabetes control and weight loss in animals during the pre-clinical animal study DIAB-A22-1 The weight loss drug market was valued at $1.90 billion in 2021 and is expected to reach $13.26 billion by 2029, growing at a CAGR of 24.7% Many drugs used to control diabetes have produced results in managing obesity, which Lexaria plans to leverage with its DehydraTECH(TM) technology Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical study to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control…

TuesdayAug 08, 2023 9:45 am

GEMXX Corp. (GEMZ) Announces Significant Progress Regarding Financing for Gold and Ammolite Mining Operations

The company offers an approach that gives them a cost-saving edge over other producers in the market Preliminary discussions have been made to shortlist engineering firms capable of conducting the necessary SK-1300 technical reports for the company’s newest gold and Ammolite assets – with anticipated completion by the end of FY-2023 GEMXX is participating in Regulation A financing, and interested investors, shareholders, institutions, and financiers, are urged to visit the company’s website for more information GEMXX (OTC: GEMZ), a mine-to-market enterprise specializing in gold, gemstone, and jewelry production, recently announced that it has made significant progress in its efforts to…

TuesdayAug 08, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates ‘Strategically Important’ New Patent Granted in the US

Lexaria recently celebrated the receipt of its 35th overall granted patent worldwide when the USPTO recently awarded US patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine” The company described the new patent as “strategically important” The patent positions the company to tap into the growing oral nicotine market and offers protection in one of the world’s leading oral nicotine markets This patent could also lead to additional subsequent patents from within this family Lexaria’s DehydraTECH-nicotine formulation is patent granted for oral nicotine delivery in the US, Canada, and Australia When Lexaria Bioscience (NASDAQ: LEXX), a global innovator…

FridayAug 04, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Incorporates New Subsidiary, Lexaria Nutraceutical Corp., for Non-Pharmaceutical, Non-Nicotine, and Non-Cannabis DehydraTECH(TM) Formulations

Lexaria Nutraceutical Corp. will keep Lexaria’s overall strategy of maximizing the company’s patented DehydraTECH(TM) technology in various markets, excluding pharmaceutical, nicotine, and cannabis molecules Lexaria Pharmaceutical Corp.’s licensing was amended so as to solely focus on pharmaceutical formulations excluding nicotine Lexaria announced in early May that its nicotine trial, NIC-H22-1, had completed dosing with results expected in the near future NIC-H22-1 is anticipated to intercede the oral nicotine pouch market, which had a global value of $2.33 billion in 2020, and is expected to grow to $21.84 billion by 2027 Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug…

ThursdayAug 03, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Joins AMACARGA, Expanding Footprint, Capabilities, and Industry Presence

Fr8Tech just announced its move to join AMACARGA to expand its capabilities to cater to the growing demands of its clients importing goods from Asia The company’s association with AMACARGA affords it exceptional expertise and adherence to industry standards, bolstering its reputation in the industry The move further compounds Fr8Tech’s aggressive partnerships and collaborations plan, having recently announced its association with Trucker Tools, an automated booking solutions platform Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and increasing shipper flexibility, visibility, and simplicity, just announced its move…

MondayJul 31, 2023 10:15 am

GEMXX Corp. (GEMZ) Is ‘One to Watch’

GEMXX has a qualified Regulation A offering in place to raise up to $6 million at $0.40 per share GEMXX’s net income for the three months ended December 31, 2022, increased to $182,992, as compared to $126,360 in the previous quarter The company’s most recent financial results filing continues to report positive net revenues for the year and no long-term debt In March 2023, GEMXX announced it had signed an Ammolite Master Supply Agreement with Canadian Ammolite Gems by Kenneth Bradley GEMXX (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources,…

FridayJul 28, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent

Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, which targets patients with advanced, metastatic non-small cell lung cancer whose disease progressed after treatment with Keytruda The company has received patent protection for the REQORSA-Keytruda drug combination in the U.S., Japan, Australia, Russia, Mexico, and China, meaning the company has secured exclusivity in many of the largest markets The granted patents, three Fast Track Designations, and positive preclinical…

FridayJul 28, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Newly Granted Patent for DehydraTECH(TM)–Nicotine by United States Patent and Trademark Office

Lexaria’s new patent includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches The global oral nicotine pouch market was valued at $4.69 billion in 2022 and is expected to grow to $11.91 billion by 2029, driven by the growing ban on e-cigarettes worldwide The white pouch category is one of the fastest-growing, tobacco-free alternatives to smoking and vaping – growing at a CAGR of 13.4% Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, has announced that the United…

ThursdayJul 27, 2023 11:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Keeping a Close Eye on FMCSA Speed Limiter Rule, Amid Growing Debate and Displeasure from OOIDA

The FMCSA (Federal Motor Carrier Safety Administration) proposed a rule mandating speed limiters for most commercial vehicles The ATA has supported the move, while OOIDA (Owner Operator Independent Drivers Association) has opposed it, terming it as an attempt to eliminate one of the few advantages they enjoy over big business The FMCSA is yet to communicate its decision on the matter, pending its review of over 15,000 comments on the issue Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and shippers with flexibility, visibility, and simplicity, is…

WednesdayJul 26, 2023 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Set to be Used in Multi-Billion Dollar Markets; On Track to have 2023 as Best Year Yet

Lexaria’s patented DehydraTECH(TM) technology enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats This unique approach to drug delivery has earned Lexaria a total of 35 patents, with many patents pending worldwide The company continues active discussions with multi-billion dollar companies for the potential use of DehydraTECH in their commercial pursuits Lexaria is also actively seeking commercial partners during 2023 and 2024 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is out on an ambitious move to address conditions with high unmet needs. This focus has allowed them…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717